RISK ASSESSMENT OF HERPESVIRUS REACTIVATION IN CHILDREN UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION WITH PROPHYLACTIC USE OF LETEMOVIR: A RETROSPECTIVE SINGLE CENTER OBSERVATIONAL STUDY (EBMT 2026) - Feb 7, 2026 - Abstract #P403; Pres time: Mar 22, 2026; 08:30 AM - 06:00 PM; Location: ePoster Area; "Letermovir (LTV), a novel drug for preventing cytomegalovirus (CMV) infection, significantly reduces the need for broad-spectrum antiviral drugs such as ganciclovir and foscarnet. Prophylactic use of LTV in pediatric transplant patients can significantly reduce the risk of CMV reactivation, but these patients also experience an increased risk of HHV6 and HHV7 reactivation due to the weakened "bypass" inhibitory effect of broad-spectrum antiviral drugs, which may prolong platelet engraftment."
Observational data • Retrospective data • Bone Marrow Transplantation • Cytomegalovirus Infection • Graft versus Host Disease • Immunology • Infectious Disease • Transplantation
|
|
Mi Zhou1; Qingwei Wang1; Senlin Zhang1; Shuwen Huang1; Jiaxiao Dong1; Zhe Liu1; Lili Huang1; Li Gao1; Jun Lu1; Peifang Xiao1; Jie Li1; Shaoyan Hu1
|